Ann Lab Med.  2020 Mar;40(2):114-121. 10.3343/alm.2020.40.2.114.

BRCA1/BRCA2 Pathogenic Variant Breast Cancer: Treatment and Prevention Strategies

• Lee A
• Moon BI
• Kim TH

• KMID: 2460908
• DOI: http://doi.org/10.3343/alm.2020.40.2.114

Abstract

Hereditary breast cancer is known for its strong tendency of inheritance. Most hereditary breast cancers are related to BRCA1/BRCA2 pathogenic variants. The lifelong risk of breast cancer in pathogenic BRCA1 and BRCA2 variant carriers is approximately 65% and 45%, respectively, whereas that of ovarian cancer is estimated to be 39% and 11%, respectively. Therefore, understanding these variants and clinical knowledge on their occurrence in breast cancers and carriers are important. BRCA1 pathogenic variant breast cancer shows more aggressive clinicopathological features than the BRCA2 pathogenic variant breast cancer. Compared with sporadic breast cancer, their prognosis is still debated. Treatments of BRCA1/BRCA2 pathogenic variant breast cancer are similar to those for BRCA-negative breast cancer, mainly including surgery, radiotherapy, and chemotherapy. Recently, various clinical trials have investigated poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor treatment for advanced-stage BRCA1/BRCA2 pathogenic variant breast cancer. Among the various PARP inhibitors, olaparib and talazoparib, which reached phase III clinical trials, showed improvement of median progression-free survival around three months. Preventive and surveillance strategies for BRCA pathogenic variant breast cancer to reduce cancer recurrence and improve treatment outcomes have recently received increasing attention. In this review, we provide an information on the clinical features of BRCA1/BRCA2 pathogenic variant breast cancer and clinical recommendations for BRCA pathogenic variant carriers, with a focus on treatment and prevention strategies. With this knowledge, clinicians could manage the BRCA1/BRCA2 pathogenic variant breast cancer patients more effectively.

Keyword

BRCA1/BRCA2 pathogenic variant; Breast cancer; Ovarian cancer; Treatment; Prevention

MeSH Terms

Breast Neoplasms*
Breast*
Disease-Free Survival
Drug Therapy
Humans
Ovarian Neoplasms
Poly(ADP-ribose) Polymerase Inhibitors
Prognosis
Radiotherapy
Recurrence
Wills
Poly(ADP-ribose) Polymerase Inhibitors

Figure

• 

  Fig. 1 Incidence of breast cancer. (A) hereditary breast cancer accounts for 5–10% of all breast cancer cases. (B) BRCA1/BRCA2 pathogenic variant breast cancer accounts for up to 60% of all hereditary breast cancer cases [97]. Copyright permission for this figure was obtained from publisher.

Reference

1. Mahdavi M, Nassiri M, Kooshyar MM, Vakili-Azghandi M, Avan A, Sandry R, et al. Hereditary breast cancer; genetic penetrance and current status with BRCA. J Cell Physiol. 2019; 234:5741–5750. PMID: 30552672.

2. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998; 62:676–689. PMID: 9497246.

3. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003; 72:1117–1130. PMID: 12677558.

4. Thompson D, Easton DF. Breast Cancer Linkage Consortium. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst. 2002; 94:1358–1365. PMID: 12237281.

5. Veronesi A, de Giacomi C, Magri MD, Lombardi D, Zanetti M, Scuderi C, et al. Familial breast cancer: characteristics and outcome of BRCA 1-2 positive and negative cases. BMC Cancer. 2005; 5:70. PMID: 15996267.

6. Debniak T, Scott RJ, Górski B, Cybulski C, van de Wetering T, Serrano-Fernandez P, et al. Common variants of DNA repair genes and malignant melanoma. Eur J Cancer. 2008; 44:110–114. PMID: 18024013.

7. Kadouri L, Hubert A, Rotenberg Y, Hamburger T, Sagi M, Nechushtan C, et al. Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations. J Med Genet. 2007; 44:467–471. PMID: 17307836.

8. Cybulski C, Górski B, Gronwald J, Huzarski T, Byrski T, Debniak T, et al. BRCA1 mutations and prostate cancer in Poland. Eur J Cancer Prev. 2008; 17:62–66. PMID: 18090912.

9. Suchy J, Cybulski C, Górski B, Huzarski T, Byrski T, Dębniak T, et al. BRCA1 mutations and colorectal cancer in Poland. Fam Cancer. 2010; 9:541–544. PMID: 20862552.

10. Moynahan ME, Chiu JW, Koller BH, Jasin M. BRCA1 controls homology-directed DNA repair. Mol Cell. 1999; 4:511–518. PMID: 10549283.

11. Moynahan ME, Pierce AJ, Jasin M. BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell. 2001; 7:263–272. PMID: 11239455.

12. Scully R, Chen J, Plug A, Xiao Y, Weaver D, Feunteun J, et al. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell. 1997; 88:265–275. PMID: 9008167.

13. Orban TI. Emerging roles of BRCA1 alternative splicing. Mol Pathol. 2003; 56:191–197. PMID: 12890739.

14. Stecklein SR, Jensen RA, Pal A. Genetic and epigenetic signatures of breast cancer subtypes. Front Biosci (Elite Ed). 2012; 4:934–949. PMID: 22201926.

15. D'Andrea AD. The Fanconi anaemia/BRCA pathway. Nat Rev Cancer. 2003; 3:23–34. PMID: 12509764.

16. Albertsen H, Plaetke R, Ballard L, Fujimoto E, Connolly J, Lawrence E, et al. Genetic mapping of the BRCA1 region on chromosome 17q21. Am J Hum Genet. 1994; 54:516–525. PMID: 8116621.

17. Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science. 1994; 265:2088–2090. PMID: 8091231.

18. Bork P, Blomberg N, Nilges M. Internal repeats in the BRCA2 protein sequence. Nat Genet. 1996; 13:22–23. PMID: 8673099.

19. Chen PL, Chen CF, Chen Y, Xiao J, Sharp ZD, Lee WH. The BRC repeats in BRCA2 are critical for RAD51 binding and resistance to methyl methanesulfonate treatment. Proc Natl Acad Sci U S A. 1998; 95:5287–5292. PMID: 9560268.

20. Wong AK, Pero R, Ormonde PA, Tavtigian SV, Bartel PL. RAD51 interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene BRCA2. J Biol Chem. 1997; 272:31941–31944. PMID: 9405383.

21. Chen J, Silver DP, Walpita D, Cantor SB, Gazdar AF, Tomlinson G, et al. Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells. Mol Cell. 1998; 2:317–328. PMID: 9774970.

22. Petrucelli N, Daly MB, Feldman GL. Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2. Genet Med. 2010; 12:245–259. PMID: 20216074.

23. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet. 1994; 343:692–695. PMID: 7907678.

24. Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst. 1999; 91:1310–1316. PMID: 10433620.

25. Kim S. Korean hereditary breast cancer. J Korean Med Assoc. 2009; 52:952–962.

26. Dai X, Cheng H, Bai Z, Li J. Breast cancer cell line classification and its relevance with breast tumor subtyping. J Cancer. 2017; 8:3131–3141. PMID: 29158785.

27. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006; 295:2492–2502. PMID: 16757721.

28. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007; 13:4429–4434. PMID: 17671126.

29. Brewster AM, Chavez-MacGregor M, Brown P. Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry. Lancet Oncol. 2014; 15:e625–e634. PMID: 25456381.

30. Peshkin BN, Alabek ML, Isaacs C. BRCA1/2 mutations and triple negative breast cancers. Breast Dis. 2010; 32:25–33. PMID: 21778580.

31. Ansquer Y, Gautier C, Fourquet A, Asselain B, Stoppa-Lyonnet D. Survival in early-onset BRCA1 breast-cancer patients. Institut Curie Breast Cancer Group. Lancet. 1998; 352:541.

32. Chappuis PO, Kapusta L, Bégin LR, Wong N, Brunet JS, Narod SA, et al. Germline BRCA1/2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer. J Clin Oncol. 2000; 18:4045–4052. PMID: 11118465.

33. Stoppa-Lyonnet D, Ansquer Y, Dreyfus H, Gautier C, Gauthier-Villars M, Bourstyn E, et al. Familial invasive breast cancers: worse outcome related to BRCA1 mutations. J Clin Oncol. 2000; 18:4053–4059. PMID: 11118466.

34. El-Tamer M, Russo D, Troxel A, Bernardino LP, Mazziotta R, Estabrook A, et al. Survival and recurrence after breast cancer in BRCA1/2 mutation carriers. Ann Surg Oncol. 2004; 11:157–164. PMID: 14761918.

35. van den Broek AJ, Schmidt MK, van't Veer LJ, Tollenaar RA, van Leeuwen FE. Worse breast cancer prognosis of BRCA1/BRCA2 mutation carriers: what's the evidence? A systematic review with meta-analysis. PLoS One. 2015; 10:e0120189. PMID: 25816289.

36. Copson ER, Maishman TC, Tapper WJ, Cutress RI, Greville-Heygate S, Altman DG, et al. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncol. 2018; 19:169–180. PMID: 29337092.

37. Baretta Z, Mocellin S, Goldin E, Olopade OI, Huo D. Effect of BRCA germline mutations on breast cancer prognosis: a systematic review and meta-analysis. Medicine (Baltimore). 2016; 95:e4975. PMID: 27749552.

38. Pierce LJ, Phillips KA, Griffith KA, Buys S, Gaffney DK, Moran MS, et al. Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. Breast Cancer Res Treat. 2010; 121:389–398. PMID: 20411323.

39. Vallard A, Magné N, Guy JB, Espenel S, Rancoule C, Diao P, et al. Is breast-conserving therapy adequate in BRCA 1/2 mutation carriers? The radiation oncologist's point of view. Br J Radiol. 2019; 92:20170657. PMID: 30810334.

40. Kirova YM, Savignoni A, Sigal-Zafrani B, de La Rochefordiere A, Salmon RJ, This P, et al. Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature. Breast Cancer Res Treat. 2010; 120:119–126. PMID: 20033769.

41. Pierce LJ, Strawderman M, Narod SA, Oliviotto I, Eisen A, Dawson L, et al. Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol. 2000; 18:3360–3369. PMID: 11013276.

42. Valachis A, Nearchou AD, Lind P. Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis. Breast Cancer Res Treat. 2014; 144:443–455. PMID: 24567198.

43. Iglehart JD. Synthetic lethality--a new direction in cancer-drug development. N Engl J Med. 2009; 361:189–191. PMID: 19553640.

44. Carey LA, Sharpless NE. PARP and cancer--if it's broke, don't fix it. N Engl J Med. 2011; 364:277–279. PMID: 21208102.

45. Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Harkin DP. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst. 2004; 96:1659–1668. PMID: 15547178.

46. Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR, Bishop DK. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA crosslinking agent cisplatin. J Biol Chem. 2000; 275:23899–23903. PMID: 10843985.

47. Fedier A, Steiner RA, Schwarz VA, Lenherr L, Haller U, Fink D. The effect of loss of BRCA1 on the sensitivity to anticancer agents in p53-deficient cells. Int J Oncol. 2003; 22:1169–1173. PMID: 12684687.

48. Tassone P, Tagliaferri P, Perricelli A, Blotta S, Quaresima B, Martelli ML, et al. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer. 2003; 88:1285–1291. PMID: 12698198.

49. Chabalier C, Lamare C, Racca C, Privat M, Valette A, Larminat F. BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. Cell Cycle. 2006; 5:1001–1007. PMID: 16639080.

50. Arun B, Bayraktar S, Liu DD, Gutierrez Barrera AM, Atchley D, Pusztai L, et al. Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. J Clin Oncol. 2011; 29:3739–3746. PMID: 21900106.

51. Kriege M, Jager A, Hooning MJ, Huijskens E, Blom J, van Deurzen CH, et al. The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer. 2012; 118:899–907. PMID: 21761396.

52. Zimmer AS, Gillard M, Lipkowitz S, Lee JM. Update on PARP inhibitors in breast cancer. Curr Treat Options Oncol. 2018; 19:21. PMID: 29644491.

53. Helleday T. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol. 2011; 5:387–393. PMID: 21821475.

54. Javle M, Curtin NJ. The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy. Ther Adv Med Oncol. 2011; 3:257–267. PMID: 22084640.

55. Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science. 2017; 355:1152–1158. PMID: 28302823.

56. Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017; 377:523–533. PMID: 28578601.

57. Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018; 379:753–763. PMID: 30110579.

58. Thomas HD, Calabrese CR, Batey MA, Canan S, Hostomsky Z, Kyle S, et al. Preclinical selection of a novel poly (ADP-ribose) polymerase inhibitor for clinical trial. Mol Cancer Ther. 2007; 6:945–956. PMID: 17363489.

59. Drew Y, Ledermann J, Hall G, Rea D, Glasspool R, Highley M, et al. Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer. Br J Cancer. 2016; 114:723–730. PMID: 27002934.

60. Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2013; 14:882–892. PMID: 23810788.

61. Lee JM, Hays JL, Annunziata CM, Noonan AM, Minasian L, Zujewski JA, et al. Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses. J Natl Cancer Inst. 2014; 106:dju089. PMID: 24842883.

62. Balmaña J, Tung NM, Isakoff SJ, Graña B, Ryan PD, Saura C, et al. Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors. Ann Oncol. 2014; 25:1656–1663. PMID: 24827126.

63. Miller K, Tong Y, Jones DR, Walsh T, Danso MA, Ma CX, et al. Cisplatin with or without rucaparib after preoperative chemotherapy in patients with triple negative breast cancer: final efficacy results of Hoosier Oncology Group BRE09-146. J Clin Oncol. 2015; 33(S15):1082.

64. Wilson RH, Evans TRJ, Middleton MR, Molife LR, Spicer J, Dieras V, et al. A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours. Br J Cancer. 2017; 116:884–892. PMID: 28222073.

65. Somlo G, Frankel PH, Luu TH, Ma CX, Arun B, Garcia AA, et al. Efficacy of the PARP inhibitor (PI) ABT- 888 (veliparib [vel]) either with carboplatin (carb) or as a single agent followed by post-progression therapy in combination with carb in patients (pts) with BRCA1- or BRCA2-(BRCA)-associated metastatic breast cancer (MBC). J Clin Oncol. 2015; 33:520.

66. Han HS, Diéras V, Robson M, Palácová M, Marcom PK, Jager A, et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/ metastatic breast cancer: randomized phase II study. Ann Oncol. 2018; 29:154–161. PMID: 29045554.

67. Tung N, Wang Y, Collins LC, Kaplan J, Li H, Gelman R, et al. Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features. Breast Cancer Res. 2010; 12:R12. PMID: 20149218.

68. Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev. 2012; 21:134–147. PMID: 22144499.

69. Larsen MJ, Kruse TA, Tan Q, Lænkholm AV, Bak M, Lykkesfeldt AE, et al. Classifications within molecular subtypes enables identification of BRCA1/BRCA2 mutation carriers by RNA tumor profiling. PLoS One. 2013; 8:e64268. PMID: 23704984.

70. Shah PD, Patil S, Dickler MN, Offit K, Hudis CA, Robson ME. Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: differences based on germline mutation status. Cancer. 2016; 122:1178–1184. PMID: 26859126.

71. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al. Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010; 376:235–244. PMID: 20609467.

72. Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015; 33:244–250. PMID: 25366685.

73. Turner NC, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke EM, et al. A Phase II study of talazoparib after platinum or cytotoxic nonplatinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations (ABRAZO). Clin Cancer Res. 2019; 25:2717–2724. PMID: 30563931.

74. Biglia N, D'Alonzo M, Sgro LG, Tomasi Cont N, Bounous V, Robba E. Breast cancer treatment in mutation carriers: surgical treatment. Minerva Ginecol. 2016; 68:548–556. PMID: 26822896.

75. Li X, You R, Wang X, Liu C, Xu Z, Zhou J, et al. Effectiveness of prophylactic surgeries in BRCA1 or BRCA2 mutation carriers: a meta-analysis and systematic review. Clin Cancer Res. 2016; 22:3971–3981. PMID: 26979395.

76. Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010; 304:967–975. PMID: 20810374.

77. Satagopan JM, Boyd J, Kauff ND, Robson M, Scheuer L, Narod S, et al. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res. 2002; 8:3776–3781. PMID: 12473589.

78. King MC, Marks JH, Mandell JB. New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003; 302:643–646. PMID: 14576434.

79. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009; 101:80–87. PMID: 19141781.

80. Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber JE, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol. 2008; 26:1331–1337. PMID: 18268356.

81. King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: national Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA. 2001; 286:2251–2256. PMID: 11710890.

82. Phillips KA, Milne RL, Rookus MA, Daly MB, Antoniou AC, Peock S, et al. Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2013; 31:3091–3099. PMID: 23918944.

83. Behan LA, Amir E, Casper RF. Aromatase inhibitors for prevention of breast cancer in postmenopausal women: a narrative review. Menopause. 2015; 22:342–350. PMID: 25692874.

84. Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, Cowens-Alvarado RL, et al. American Cancer Society/American Society of Clinical Oncology breast cancer survivorship care guideline. CA Cancer J Clin. 2016; 66:43–73. PMID: 26641959.

85. NCCN. The NCCN Clinical Practice Guidelines in Oncology, genetic/familial high-risk assessment: breast and ovarian. 3.2019 version. 2019.

86. US Preventive Services Task Force. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer US Preventive Services Task Force Recommendation Statement. JAMA. 2019; 322:652–665. PMID: 31429903.

87. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997; 336:1401–1408. PMID: 9145676.

88. Burke W, Daly M, Garber J, Botkin J, Kahn MJ, Lynch P, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer II BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA. 1997; 277:997–1003. PMID: 9091675.

89. Scheuer L, Kauff N, Robson M, Kelly B, Barakat R, Satagopan J, et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol. 2002; 20:1260–1268. PMID: 11870168.

90. Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007; 57:75–89. PMID: 17392385.

91. Woodward ER, Sleightholme HV, Considine AM, Williamson S, McHugo JM, Cruger DG. Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population risk women is ineffective. BJOG. 2007; 114:1500–1509. PMID: 17903229.

92. Baumiller RC, Cunningham G, Fisher N, Fox L, Henderson M, Lebel R, et al. Code of ethical principles for genetics professionals: an explication. Am J Med Genet. 1996; 65:179–183. PMID: 9240740.

93. Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol. 2004; 22:735–742. PMID: 14966099.

94. Kirchhoff T, Satagopan JM, Kauff ND, Huang H, Kolachana P, Palmer C, et al. Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer. J Natl Cancer Inst. 2004; 96:68–70. PMID: 14709740.

95. Niell BL, Rennert G, Bonner JD, Almog R, Tomsho LP, Gruber SB. BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer. J Natl Cancer Inst. 2004; 96:15–21. PMID: 14709734.

96. Garber JE, Syngal S. One less thing to worry about: the shrinking spectrum of tumors in BRCA founder mutation carriers. J Natl Cancer Inst. 2004; 96:2–3. PMID: 14709725.

97. Korean Hereditary Breast Cancer Study group. Hereditary Breast Cancer. 1st ed. Gyeonggi-do: KOONJA publishing;2012. p. 393–394.